PALO ALTO, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Telik, Inc. announced that company management will provide a corporate overview at the UBS Global Life Sciences Conference in New York City on Wednesday, September 26, 2007 at 12:30 p.m. Eastern time (9:30 a.m. Pacific time). Telik’s presentation will be webcast live and will be available for replay through the Telik website, http://www.telik.com, through October 3, 2007.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidates are TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non- small cell lung cancer; and TELINTRA(TM), which is in clinical development for the treatment of myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates.
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director of Corporate Communications ofTelik, Inc., +1-650-845-7728, cdeguzman@telik.com
Web site: http://www.telik.com/
